Back to Interventions

Substance / Medication

Cromolyn

SNOMED 372672009 UMLS C0086073

Overview

Active Ingredient

cromolyn

RxNorm CUI

42612

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Inflammatory bowel disease

Airway hyperreactivity

Nonseasonal allergic rhinitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 4537-7

secondary

LOINC 26464-8

secondary

C reactive protein

LOINC 1988-5

primary

LOINC 711-2

primary

LOINC 19113-0

primary

LOINC 770-8

primary

Clinical Trials

352 trials linked to this intervention

352

Total Trials

40

Recruiting

114

With Results

Recent Trials

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

NCT00001406Recruiting800 enrolled

Role of Genetic Factors in the Development of Lung Disease

NCT00001532Recruiting3500 enrolled

Sample Collections From the Airways of Asthmatic Patients

NCT00001888Completed574 enrolled

Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)

NCT00070707Phase 4Completed188 enrolled

Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)

NCT00092092Phase 4Completed71 enrolled

View all 352 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Cromolyn sodium for the prevention of chronic lung disease in preterm infants.

Ng Geraldine, Ohlsson Arne · Cochrane Database Syst Rev · 2017

PMID: 28114736Meta-AnalysisFull text (PMC)

Cromolyn sodium for the prevention of chronic lung disease in preterm infants.

Ng Geraldine, Ohlsson Arne · Cochrane Database Syst Rev · 2012

PMID: 22696332Meta-Analysis

Cromolyn sodium for the prevention of chronic lung disease in preterm infants.

Ng G Y, Ohlsson A · Cochrane Database Syst Rev · 2001

PMID: 11406065Meta-Analysis

A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.

Lieberman Jay Adam, Zhang Jie, Whitworth John et al. · Ann Allergy Asthma Immunol · 2018

PMID: 29544738RCT

Cromolyn-mediated improvement of intestinal barrier function is associated with enhanced piglet performance after weaning.

Mereu Alessandro, Tedó Gemma, Moeser Adam J et al. · BMC Vet Res · 2015

PMID: 26510713RCTFull text (PMC)

Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.

Feily Amir, Dormanesh Benafshe, Ghorbani Ali Reza et al. · Int J Clin Pharmacol Ther · 2012

PMID: 22732382RCT

Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study.

Vessal Ghazal, Sagheb Mohammad Mehdi, Shilian Saman et al. · Nephrol Dial Transplant · 2010

PMID: 20007756RCT

Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations.

Al-Ghananeem Abeer M, Sandefer Erik P, Doll Walter J et al. · Int J Pharm · 2008

PMID: 18329197RCT

Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation.

Elbary Ahmed Abd, El-laithy Hanan M, Tadros Mina I · Arch Pharm Res · 2007

PMID: 17679559RCT

Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray.

Karimi Mehran, Zekavat Omid R, Sharifzadeh Sedigeh et al. · Am J Hematol · 2006

PMID: 16941613RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Allergy & Immunology (Internal Medicine) Physician

Internal Medicine — Allergy & Immunology

NUCC 207RA0201X

Gastroenterology Physician

Internal Medicine — Gastroenterology

NUCC 207RG0100X

Pulmonary Disease Physician

Internal Medicine — Pulmonary Disease

NUCC 207RP1001X

Find a Provider

Health Goals

Goals connected through associated conditions

Improve Gut Health Support Respiratory Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Cromoglicic acid (substance)
SNOMED CT: 372672009
UMLS CUI: C0086073
RxNorm CUI: 42612

Clinical Data

This intervention maps to 16 entities in the Healos knowledge graph.

4

Conditions

6

Biomarkers

4

Specialists

0

Symptoms

352

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.